nurture.farm – a Digital Platform for Sustainable Agriculture Scales up to Become Part of the OpenAg ™ Network
nurture.farm – a digital platform for growers, farming communities and food systems, is scaling and expanding its global reach as a part of the OpenAg™ network. The OpenAg™ network was conceived by UPL Ltd, a world leader in sustainable agriculture.
The nurture.farm platform fosters resilient farmers, making agriculture simple, profitable and sustainable for generations to come through technology-led solutions covering every step of the farming life cycle. nurture.farm, which was incubated by UPL, will operate as an open platform in the supply of products, innovation and mechanisation.
Dhruv Sawhney, COO and Business Head, nurture.farm said:
“The impact of nurture.farm on farming communities represents significant progress in advancing our mission to reimagine sustainability for agriculture across the world and help farmers secure a brighter future. Our digital platform is helping farming communities that are facing a number of competing external risks and challenges including variable weather patterns, financial insecurity, and lack of access to information and mechanisation. We are democratising technology, creating a shared infrastructure and uniting farmers and buyers under a global community committed to driving sustainability. We look forward to taking our revolutionary platform to new markets, as we endeavour to change the game for farmers and make food systems more sustainable.”
“We are pleased to welcome nurture.farm to the OpenAg™ network, and excited for the role they will play in our mission to unlock opportunities for farmers, food security and sustainable agriculture worldwide,” says Carlos Pellicer – COO, UPL Ltd. “By increasing accessibility to the solutions, technologies, and services that growers need to thrive, nurture.farm is creating a truly customer-centric ecosystem that delivers on the promise of shared prosperity and feeds sustainable growth for all.”
Through a holistic approach, nurture.farm has developed a comprehensive ecosystem of integrated solutions to increase accessibility, connectivity and resilience, and secure sustainable outcomes. The key solutions include:
- farm – supports farmers at every step of the farming life cycle by driving precision agriculture at scale through crop health solutions, advisory services, farm level mechanisation & digitization.
- retail – enables retailers & farmers to purchase authentic and high-quality agricultural input products (crop protection, seeds, farm equipment, feeds, and more).
- trade – connects farmers and buyers through end-to-end traceability of sustainable practices, transparency of information, and convenient access to markets.
- sustain – drives sustainable agriculture globally through regenerative practices and reward farmers for adopting them
Launched in early 2020, nurture.farm has since grown both in scale and impact, now supporting over 1 million farmers and 50,000 retailers on its digital platform, with over 2.5 million acres of farmland serviced. The platform has been well received by users across India, and several promising pilot projects are underway in other key markets including the U.S., South Africa, Brazil and Australia.
As a part of its mission to create sustainable food systems, nurture.farm is encouraging regenerative agriculture practices through its selection of products, services, and projects. It is driving numerous new programs, including stubble burning avoidance programs, biological products, carbon credits and reward programs to advance this mission.
Jai Shroff, Global CEO of UPL Ltd. said:
“nurture.farm is one of the most exciting initiatives within the OpenAg™ network, unlocking opportunities for farmers and food systems worldwide, delivering shared prosperity for our growers and their communities, and supporting environmental sustainability. The success of nurture.farm’s operations in India, as well as its pilot projects further afield, demonstrate the value creation the platform provides. I look forward to supporting nurture.farm’s further expansion and impact.”
Notes to Editors:
UPL Ltd. (NSE: UPL & BSE: 512070) is a global provider of sustainable agriculture products & solutions, with annual revenue exceeding $5 billion. We are a purpose-led company. Through OpenAg™, UPL is focused on facilitating progress for the entire agricultural value chain. We are building a network that redefines the way an entire industry thinks and works – open to fresh ideas, innovative ways and new answers as we strive towards our mission to make every single food product more sustainable.
As one of the largest agriculture solutions companies worldwide, our robust portfolio consists of biologicals and traditional crop protection solutions with more than 13,600 registrations. We are present in more than 130 countries, represented by more than 10,000 colleagues globally. For more information about our integrated portfolio of solutions across the food value chain including seeds, post-harvest, as well as physical and digital services, please visit upl-ltd.com and follow us on LinkedIn, Twitter, Instagram and Facebook
OpenAg™ is an open network to create sustainable growth for all – no limits, no borders. Together we are reimagining sustainability, bringing all of the different players across the food system – from farmers to food producers to consumers - in the spirit of collaboration to change how the whole industry thinks, works and evolves. Through agility, creativity and cooperation, and from new technologies, seeds, and biological solutions, to digital platforms, training programmes, and partnerships, OpenAg™ is an open door, an open heart, and an open invitation to work together to build sustainable, resilient, beneficial food systems.
To learn more about OpenAg™ visit upl-ltd.com/our-story/open-ag
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blackstone and Hudson Pacific Properties Announce Plans for New World-Class Film and TV Studios in the UK2.8.2021 09:00:00 CEST | Press release
Blackstone (NYSE: BX) and Hudson Pacific Properties (NYSE: HPP) plan to create a major new centre for film, TV and digital production in Broxbourne, Hertfordshire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005278/en/ Artist Impression No. 1 (Photo: Business Wire) Funds managed by Blackstone Real Estate Partners and Hudson Pacific Properties acquired a 91-acre site, 17 miles north of central London, through a joint venture for £120 million. The acquisition, with an expected total investment of over £700 million, will be the partners’ first expansion of their Sunset Studios platform outside of the US. The proposed development, which is subject to planning permission, would transform the site into one of the largest world-class film and television studio campuses. The project is expected to create over 4,500 permanent jobs for Broxbourne and the surrounding community and contribute more than £300 million annually int
AMICOGEN Inc. and Lysando AG Bring Partnership to the Next Level With Ownership Participations in Each Other’s Companies2.8.2021 08:00:00 CEST | Press release
South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN. The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were negotiated with a 300 Mio. Euro evaluation of Lysando. Other shareholders of Lysando continue to be majority owner and Chairman of the Board Markus Graf Matuschka von Greiffenclau, Bangkok based SCG, and Lysando’s employees. The companies have already a productive partnership in place, based on Lysando´s leading platform Artilysin®. It is a globally patented, sustainable and highly effective technology, fighting resistance of microbes, as an alternative to antibiotics and other antimicrobial treatments. „I am very happy and proud to welcome AMICOGEN as a new shareholder of Lysando. AMICOGEN being such a strong and successfully operating CDMO, A
Leicester’s Hospitals Awards Deenova a Unit Dose Pharmacy Automation 15 Year Contract2.8.2021 08:00:00 CEST | Press release
Deenova reported today it signed its first ever contract in the United Kingdom, and established operations in Europe’s second largest GDP health care market, with the NHS being the eight largest employer in the world. Deenova was selected by University Hospitals of Leicester NHS Trust as the best solution amongst 8 of Deenova's competitors in United Kingdom and the United States of America. Claire Ellwood, chief pharmacist at University Hospitals of Leicester NHS Trust, said: “We’re proud to be working with Deenova to deploy the first unit dose closed loop medicines management system in the UK. Every year, we administer millions of medication doses so it’s vital our processes are as safe and efficient as possible. The partnership with Deenova will increase automation within our medication processes helping to reduce errors and wastage as well as freeing up staff time for other care and tasks. After a successful pilot, we are pleased to start planning the roll out across our three hospi
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders2.8.2021 07:00:00 CEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210801005028/en/ Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Exicure Inc. (NASDAQ: XCUR) have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease and Angelman syndrome. Oligonucleotides are synthetic structures of nucleic acids that can be used to modulate gene expression via a range of processes, including gene activation, inhibition, and splice-modulation. These molecules have demonstrated potential in many different therapeutic areas.1 Achieving efficient oligonucleotide delivery to target organs and tissues, including the brain, remains a major limitation to their use.1,2 Exicure’s SNAs provide distinct chemical and biochemical properties to oligonucleotides. I
Arqit Releases QuantumCloud™ to Deliver Stronger, Simpler Encryption2.8.2021 06:20:00 CEST | Press release
Arqit Limited (“Arqit”), a leader in quantum encryption technology announces the release of the first version of its service, QuantumCloud™ 1.0. This Platform‑as‑a‑Service software enables customers to secure the communications channels and data of any cloud, edge or end-point device. The service combines transformational and unique advances in both quantum and classical cryptography. The release of QuantumCloud™ 1.0 allows customers to secure devices globally by providing a strong device authentication capability, over which is layered the agreement of symmetric keys between authenticated and authorised devices. Importantly, since there are no asymmetric cryptographic primitives used within the trustless key agreement protocol, the keys can be regarded as safe against future attack using Shor’s algorithm running on a quantum computer. A range of other features will be added in future quarters, culminating in the launch of Arqit’s proprietary quantum satellites, which is targeted for 2
Arqit Registration Statement Related to Business Combination With Centricus Acquisition Corp. Declared Effective By SEC2.8.2021 06:04:00 CEST | Press release
Arqit Limited (“Arqit”), a leader in quantum encryption technology today announced the Registration Statement on Form F-4 in connection with the previously announced business combination (the “Business Combination”) with Centricus Acquisition Corp. (“Centricus”) (Nasdaq: CENHU, CENH, CENHUW), a publicly-listed special purpose acquisition company, has been declared effective by the Securities and Exchange Commission (the “SEC”). Upon closing, the ordinary shares and warrants of Arqit Quantum Inc., a company formed for purposes of completing the Business Combination, will be listed on NASDAQ under the new ticker symbols “ARQQ” and “ARQQW.” The boards of directors of Arqit and Centricus have unanimously approved the Business Combination, and Centricus has set 9:00 a.m. ET on August 31, 2021 as the time and date for an extraordinary general meeting of shareholders to approve the proposals associated with the Business Combination. The proxy statement/prospectus contains important informatio
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie2.8.2021 01:30:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30, 2021 (IST) to uphold the Irish Revenue Commissioners’ position related to the treatment of a break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. (“AbbVie”). Shire was acquired by Takeda in January 2019. Takeda intends to challenge this outcome through all available legal means including appealing the decision to the Irish courts. On November 28, 2018, Shire received a tax assessment from the Irish Revenue Commissioners for 398 million EUR. This assessment sought to tax a 1,635 million USD break fee Shire received from AbbVie in connection with the terminated offer to acquire Shire made by AbbVie in 2014. Takeda appealed this assessment, and in late 2020 a hearing took place before the Irish Tax Appeals Commission. While Takeda is continuing to assess the substance of the decision, the company will record a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom